Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.54 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | GLP1R | P43220 | 8/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22790738 | 0.88 | MEN1 (0.52) | CASP2FAAHEPHX2TSHRRECQL | |
| SCHEMBL22856128 | 0.87 | MEN1 (0.53) | CASP2FAAHEPHX2RECQL | |
| SCHEMBL25913029 | 0.87 | MEN1 (0.45) | CASP2GLP1R | |
| SCHEMBL24674803 | 0.87 | MEN1 (0.45) | CASP2GLP1R | |
| SCHEMBL23945685 | 0.84 | SMN1; SMN2 (0.44) | CASP2FAAHEPHX2TSHRRECQL | |
| SCHEMBL25925312 | 0.84 | CES2 (0.59) | CASP2NAAAFAAHGLP1REPHX2 | |
| SCHEMBL23945522 | 0.82 | EPHX2 (0.36) | CASP2FAAHEPHX2TSHRRECQL | |
| SCHEMBL21501564 | 0.82 | GLP1R (0.45) | CASP2FAAHGLP1REPHX2TSHR | |
| SCHEMBL23696205 | 0.82 | EPHX2 (0.36) | CASP2FAAHEPHX2TSHRRECQL | |
| SCHEMBL24977644 | 0.81 | GLP1R (0.52) | CASP2NAAAFAAHGLP1REPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CASP2 406/4885NAAA 1342/4885FAAH 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.